Informační systém MU
ŽÁČKOVÁ, Daniela, Hana KLAMOVÁ, Jan MUŽÍK, Edmund CMUNT, Zdeněk RÁČIL, Kateřina MACHOVÁ POLÁKOVÁ, Dana DVOŘÁKOVÁ, Tomáš JURČEK, Filip RÁZGA, Petr CETKOVSKÝ, Ladislav DUŠEK and Jiří MAYER. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Leukemia & Lymphoma. London: Informa Healthcare, Gordon and Breach, 2013, vol. 54, No 10, p. 2310-2313. ISSN 1042-8194. doi:10.3109/10428194.2013.772173.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Authors ŽÁČKOVÁ, Daniela (203 Czech Republic, guarantor, belonging to the institution), Hana KLAMOVÁ (203 Czech Republic), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Edmund CMUNT (203 Czech Republic), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Dana DVOŘÁKOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic), Filip RÁZGA (703 Slovakia, belonging to the institution), Petr CETKOVSKÝ (203 Czech Republic), Ladislav DUŠEK (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Leukemia & Lymphoma, London, Informa Healthcare, Gordon and Breach, 2013, 1042-8194.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.605
RIV identification code RIV/00216224:14740/13:00070872
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3109/10428194.2013.772173
UT WoS 000324589800042
Keywords in English chronic myeloid leukemia; formal clinical trials; dasatinib; imatinib
Tags podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 10. 4. 2014 09:58.
Abstract
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Displayed: 29. 11. 2022 11:07